Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.

The New England journal of medicine·2026
Same author

Posttuberculosis Lung Disease in Adolescents in Lima, Peru.

Pediatrics·2026
Same author

Computer-aided detection for radiological disease severity classification on chest radiograph in children with intra-thoracic tuberculosis.

PLOS global public health·2026
Same author

Persistent evidence practice gap in antibiotic use for community acquired pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Tuberculosis research principles and priorities in children and adolescents: an international consensus statement.

The Lancet. Child & adolescent health·2026
Same author

Molecular diagnostic tests for isoniazid-resistant tuberculosis: a scoping review.

The Lancet. Microbe·2026

Related Experiment Videos

Drug-resistant tuberculosis: pediatric guidelines.

Mona Al-Dabbagh1, Keswadee Lapphra, Rumi McGloin

  • 1Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

The Pediatric Infectious Disease Journal
|February 8, 2011
PubMed
Summary
This summary is machine-generated.

Drug-resistant tuberculosis (TB) treatment in children requires multiple medications for extended durations. This review focuses on managing adverse effects of pediatric drug-resistant TB therapy in high-resource settings.

Related Experiment Videos

Area of Science:

  • Infectious Diseases
  • Pediatric Medicine
  • Pharmacology

Background:

  • Drug-resistant Mycobacterium tuberculosis (TB) poses a significant global health challenge.
  • Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) necessitate complex treatment regimens.
  • Pediatric TB management, especially with drug resistance, requires specialized approaches.

Purpose of the Study:

  • To review the current literature on the treatment of pediatric drug-resistant TB.
  • To outline strategies for monitoring adverse effects associated with these treatments.
  • To provide guidance for high-resource, low-TB burden settings.

Main Methods:

  • Systematic literature review of studies on pediatric drug-resistant TB treatment.
  • Analysis of reported adverse events and their management.
  • Synthesis of data relevant to clinical practice in specific settings.

Main Results:

  • Treatment of pediatric drug-resistant TB involves multiple drugs over prolonged periods.
  • Adverse effects are common and require vigilant monitoring and management.
  • Specific challenges exist in high-resource settings with low TB prevalence.

Conclusions:

  • Effective management of pediatric drug-resistant TB requires a comprehensive approach to treatment and adverse event monitoring.
  • Guidelines are needed to optimize therapy and minimize toxicity in children.
  • Further research is warranted to improve outcomes for this vulnerable population.